Indoco Remedies arm begins commercial production of Pharmaceutical Intermediates

Medical Dialogues team had earlier reported that Warren Remedies had commenced its commercial production on March 1, 2024, from its Greenfield manufacturing facility located at Aurangabad, Maharashtra, to manufacture Oral Care Products.

Read also: Indoco Remedies arm commences commercial production of oral care products

Indoco is a fully integrated, research-oriented pharmaceutical company with pa resence in 55 countries. The Company’s turnover is US$ 200 million with a human capital of 6000 employees, including over 300 skilled scientists and Field Staff.

The Company has nine manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including the USFDA and UK-MHRA.

Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000 doctors belonging to various specialties.

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.